Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients | Small Molecules
Hits: 574 LUND, Sweden I March 1, 2021 I Oncorena, dedicated to developing a unique and potential breakthrough therapy for metastatic renal cancer, today announces the Swedish Medical Products Agency's approval of the Phase 1/2 of First in Patient trial of the first-in-class compound, orellanine in patients with metastatic renal cancer in dialysis. Preclinical evidence shows that orellanine, a well known fungus toxin, specifically exerts powerful anti-tumor effects on metastatic renal cancer in different preclinical models. Orellanine has a unique mode of action. All preclinical activitie...
Source: pipelinereview.com